35Pharma to be Acquired by GSK to Accelerate Development of HS235, a Potential Best-in-Class Investigational Medicine for Pulmonary Hypertension (PH)

StockNews.AI · 1 minute

BullishLong TermCorporate DevelopmentsGSK

High Materiality8/10

Information

MONTREAL, Feb. 25, 2026 (GLOBE NEWSWIRE) -- 35Pharma, a Canada-based, private, clinical-stage biopha...

Original source

AI Summary

GSK has announced the acquisition of 35Pharma for $950 million, gaining HS235, a promising treatment for pulmonary hypertension. This move is strategic as the global market for pulmonary hypertension therapies is projected to hit $18 billion by 2032, and HS235 may address critical treatment limitations, potentially enhancing GSK's market position.

Sentiment Rationale

Historical acquisitions in biotech often lead to stock price increases, especially when promising products are acquired. GSK's entry into the pulmonary hypertension market with HS235 aligns with industry growth trajectories.

Trading Thesis

Investing in GSK is favorable due to this strategic acquisition, with potential growth in the coming years.

Market-Moving

GSK's acquisition of HS235 positions it in a high-potential market.
Expected regulatory approvals could lead to significant revenue opportunities.
Successful trial outcomes for HS235 may dramatically increase GSK's valuation.
HS235 addresses unmet medical needs, enhancing competitive positioning in PH.

Key Facts

GSK acquires 35Pharma for $950 million, gaining HS235.
HS235 targets pulmonary hypertension, a market expected to reach $18 billion.
The drug may reduce bleeding risks and provide metabolic benefits.
HS235 is in imminent trials for PAH and PH-HFpEF treatments.
GSK aims to enhance its respiratory and inflammatory disease portfolio.

Companies Mentioned

35Pharma (N/A): Developer of HS235, now part of GSK's pipeline.

Corporate Developments

This acquisition fits within Corporate Developments as it significantly boosts GSK's pipeline for pulmonary hypertension. The strategic introduction of HS235 aligns with GSK’s broader focus on respiratory and inflammatory diseases.